Rohit Lal

2.2k total citations
46 papers, 1.6k citations indexed

About

Rohit Lal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Rohit Lal has authored 46 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Rohit Lal's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Rohit Lal is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Rohit Lal collaborates with scholars based in United Kingdom, United States and Italy. Rohit Lal's co-authors include Yvonne Summers, Carla Visseren‐Grul, Fiona Maxwell, Mayukh Das, Daniel C. Christoph, D. Ferry, T. Benepal, J. Cadranel, James Spicer and Paul Cane and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Rohit Lal

43 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rohit Lal United Kingdom	18	691	554	489	231	200	46	1.6k
Li Ren Kong China	23	646 0.9×	501 0.9×	887 1.8×	476 2.1×	224 1.1×	77	2.0k
Geraldine O’Sullivan Coyne United States	17	630 0.9×	305 0.6×	361 0.7×	157 0.7×	185 0.9×	82	1.2k
Yu Sun China	20	553 0.8×	380 0.7×	456 0.9×	311 1.3×	132 0.7×	93	1.5k
Eric T. Kimchi United States	27	1.1k 1.5×	504 0.9×	588 1.2×	382 1.7×	332 1.7×	103	2.1k
Wenjie Ma China	22	556 0.8×	438 0.8×	535 1.1×	350 1.5×	100 0.5×	118	1.5k
Stefan C. Grant United States	22	786 1.1×	372 0.7×	524 1.1×	176 0.8×	292 1.5×	45	1.4k
Francesco Sabbatino Italy	23	992 1.4×	278 0.5×	594 1.2×	249 1.1×	479 2.4×	96	1.9k
Kangsheng Gu China	22	661 1.0×	480 0.9×	521 1.1×	335 1.5×	279 1.4×	119	1.8k
Dean A. Fennell United Kingdom	29	666 1.0×	1.0k 1.8×	809 1.7×	264 1.1×	90 0.5×	73	2.0k
Shumei Yan China	22	458 0.7×	312 0.6×	619 1.3×	365 1.6×	193 1.0×	58	1.3k

Countries citing papers authored by Rohit Lal

Since Specialization

Citations

This map shows the geographic impact of Rohit Lal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohit Lal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohit Lal more than expected).

Fields of papers citing papers by Rohit Lal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rohit Lal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohit Lal. The network helps show where Rohit Lal may publish in the future.

Co-authorship network of co-authors of Rohit Lal

This figure shows the co-authorship network connecting the top 25 collaborators of Rohit Lal. A scholar is included among the top collaborators of Rohit Lal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rohit Lal. Rohit Lal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garon, Edward B., Rina Hui, Natasha B. Leighl, et al.. (2025). 3208P 10-year outcomes from clinical trials of pembrolizumab (pembro) monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). Annals of Oncology. 36. S1099–S1100.

Lal, Rohit, et al.. (2024). Unraveling Antiseizure Medication Adherence in Paediatric Epilepsy: Implications for Clinical Practice and Patient Care. Epilepsy & Behavior. 161. 110089–110089.

Lee, Siow Ming, Sunil Upadhyay, C. Lewanski, et al.. (2019). The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy. European Journal of Cancer. 120. 86–96. 5 indexed citations

Califano, Raffaele, Rohit Lal, C. Lewanski, et al.. (2018). Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice. Future Oncology. 14(23). 2415–2431. 27 indexed citations

Banna, Giuseppe Luigi, Andrea Camerini, Giuseppe Bronte, et al.. (2018). Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. Anticancer Research. 38(6). 3689–3697. 30 indexed citations

Banna, Giuseppe Luigi, Héctor Soto Parrà, Marine Castaing, et al.. (2017). Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. Anticancer Research. 37(7). 3723–3728. 4 indexed citations

Califano, Raffaele, Alastair Greystoke, Rohit Lal, Joyce Thompson, & Sanjay Popat. (2017). Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer. Lung Cancer. 111. 51–58. 15 indexed citations

Cree, Ian A., Richard Booton, Paul Cane, et al.. (2016). PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 69(2). 177–186. 65 indexed citations

Summers, Yvonne, J. Cadranel, T. Benepal, et al.. (2016). Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews. 44. 42–50. 311 indexed citations

10.

Karapanagiotou, Eleni, et al.. (2015). Duration and Tolerance of Maintenance Pemetrexed (MPEM) Treatment for Advanced Non-Small Cell Lung Cancer. Annals of Oncology. 26. i29–i29.

11.

Lal, Rohit, Gunnar Hillerdal, Riyaz Shah, et al.. (2015). Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 89(2). 154–160. 21 indexed citations

12.

Giaccone, Giuseppe, Lyudmila Bazhenova, John Nemunaitis, et al.. (2015). A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. European Journal of Cancer. 51(16). 2321–2329. 199 indexed citations

13.

Lang-Lazdunski, Loı̈c, Andrea Billè, Sophie Papa, et al.. (2014). Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience. Journal of Thoracic and Cardiovascular Surgery. 149(2). 558–566. 56 indexed citations

14.

Brunetto, André T., Joo Ern Ang, Rohit Lal, et al.. (2013). First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(19). 5494–5504. 41 indexed citations

15.

Papa, Sophie, Sanjay Popat, Riyaz Shah, et al.. (2013). Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. Journal of Thoracic Oncology. 8(6). 783–787. 62 indexed citations

16.

Lal, Rohit, Nawel Bourayou, Gunnar Hillerdal, et al.. (2013). Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health and Quality of Life Outcomes. 11(1). 163–163. 10 indexed citations

17.

Lee, Siow Ming, Iftekhar Khan, Sunil Upadhyay, et al.. (2012). First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 13(11). 1161–1170. 133 indexed citations

18.

Pennycuick, Adam, Thomas Simpson, Danielle Crawley, et al.. (2012). Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. International Journal of Clinical Practice. 66(8). 748–752. 16 indexed citations

19.

Cleator, Susan, Andreas Makris, S. Ashley, Rohit Lal, & T.J. Powles. (2005). Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Annals of Oncology. 16(2). 267–272. 56 indexed citations

20.

Sirohi, Bhawna, R Powles, S Kulkarni, et al.. (2001). Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplantation. 28(1). 29–37. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact